Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2000

01-10-2000 | ORIGINAL ARTICLE

Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcγRI and the epidermal growth factor receptor

Authors: Paul K. Wallace, Jean-Loup Romet-Lemonne, Mohammed Chokri, Lloyd H. Kasper, Michael W. Fanger, Camilo E. Fadul

Published in: Cancer Immunology, Immunotherapy | Issue 9/2000

Login to get access
Metadata
Title
Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcγRI and the epidermal growth factor receptor
Authors
Paul K. Wallace
Jean-Loup Romet-Lemonne
Mohammed Chokri
Lloyd H. Kasper
Michael W. Fanger
Camilo E. Fadul
Publication date
01-10-2000
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2000
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620000142

Other articles of this Issue 9/2000

Cancer Immunology, Immunotherapy 9/2000 Go to the issue

ORIGINAL ARTICLE

Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas

ORIGINAL ARTICLE

Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides

ORIGINAL ARTICLE

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

ORIGINAL ARTICLE

Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas

ORIGINAL ARTICLE

Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines

OriginalPaper

Erratum: Cancer Immunol Immunother (2000) 49: 314–318

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits